1 nth after chemotherapy, 38% of patients were azoospermic, 52% had counts < 1 million/ mL, and 10% had

2 raditionally considered sterile, men who are azoospermic after chemotherapy can be treated with micro

3 rence in sperm DNA integrity between the non-azoospermic and control groups (9%, 5-13, vs 11%, 7-16;

4                                  Men who are azoospermic and have had prior cytotoxic therapy make up

5 ment was normal, but all PTM-ARKO males were azoospermic and infertile.

6                   Ten (30%) individuals were azoospermic and six (18%) oligozoospermic (sperm concent

7                                   In the non-azoospermic cancer survivor group, inhibin B concentrati

8 A expression was observed in GRTH-null mice (azoospermic due to failure of spermatids to elongate).

9 cific expression and are thus candidates for azoospermic factor (AZF).

10 entration was significantly lower in the non-azoospermic group than in controls (median 37.1 x 10(6)/

11  in location to those previously reported in azoospermic individuals.

12                            Analysis of three azoospermic male patients has shown that DFFRY is delete

13 l procedure to try to find spermatozoa in an azoospermic man.

14 CSI are effective treatment options for many azoospermic men after chemotherapy.

15 suggest that GnRH agonist treatment given to azoospermic men after cytotoxic therapy for cancer may s

16      We observed that 10% of non-obstructive azoospermic men had significantly lower recombination fr

17 fined deletion breakpoints in two unrelated, azoospermic men with AZFa deletions.

18  germ cells and its partial deletion in some azoospermic or severely oligospermic males provide evide

19                       Samples of DNA from 19 azoospermic patients with maturation arrest and 75 norma

20 the serum level of inhibin B for identifying azoospermic survivors was 45.0%, and the positive predic